X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA NOVARTIS ALEMBIC PHARMA/
NOVARTIS
 
P/E (TTM) x 29.6 364.8 8.1% View Chart
P/BV x 6.8 18.0 37.6% View Chart
Dividend Yield % 0.7 1.6 43.4%  

Financials

 ALEMBIC PHARMA   NOVARTIS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
NOVARTIS
Mar-16
ALEMBIC PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs792982 80.6%   
Low Rs443556 79.6%   
Sales per share (Unadj.) Rs167.0252.9 66.0%  
Earnings per share (Unadj.) Rs38.262.1 61.4%  
Cash flow per share (Unadj.) Rs42.063.3 66.3%  
Dividends per share (Unadj.) Rs4.0010.00 40.0%  
Dividend yield (eoy) %0.61.3 49.8%  
Book value per share (Unadj.) Rs84.9363.6 23.3%  
Shares outstanding (eoy) m188.5231.96 589.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.0 121.5%   
Avg P/E ratio x16.212.4 130.7%  
P/CF ratio (eoy) x14.712.2 121.0%  
Price / Book Value ratio x7.32.1 343.8%  
Dividend payout %10.516.1 65.1%   
Avg Mkt Cap Rs m116,38324,580 473.5%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m4,2141,801 233.9%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m31,4878,083 389.5%  
Other income Rs m55829 6.6%   
Total revenues Rs m31,5428,913 353.9%   
Gross profit Rs m10,060234 4,295.4%  
Depreciation Rs m72237 1,967.6%   
Interest Rs m372 2,044.4%   
Profit before tax Rs m9,3561,025 912.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-217 -9.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m2,160752 287.3%   
Profit after tax Rs m7,1941,986 362.2%  
Gross profit margin %31.92.9 1,102.7%  
Effective tax rate %23.173.4 31.5%   
Net profit margin %22.824.6 93.0%  
BALANCE SHEET DATA
Current assets Rs m15,06612,678 118.8%   
Current liabilities Rs m7,6742,433 315.4%   
Net working cap to sales %23.5126.7 18.5%  
Current ratio x2.05.2 37.7%  
Inventory Days Days6733 204.8%  
Debtors Days Days4122 180.7%  
Net fixed assets Rs m8,23769 11,903.8%   
Share capital Rs m377160 235.9%   
"Free" reserves Rs m15,41611,460 134.5%   
Net worth Rs m16,00511,621 137.7%   
Long term debt Rs m00-   
Total assets Rs m24,59414,400 170.8%  
Interest coverage x255.2570.5 44.7%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.6 228.1%   
Return on assets %29.413.8 213.0%  
Return on equity %44.917.1 263.0%  
Return on capital %58.723.6 248.9%  
Exports to sales %55.70.7 7,484.3%   
Imports to sales %10.418.6 56.1%   
Exports (fob) Rs m17,55160 29,154.2%   
Imports (cif) Rs m3,2831,503 218.5%   
Fx inflow Rs m17,811186 9,560.1%   
Fx outflow Rs m5,3181,821 292.1%   
Net fx Rs m12,493-1,635 -764.3%   
CASH FLOW
From Operations Rs m9,3042,531 367.6%  
From Investments Rs m-3,105-8,270 37.5%  
From Financial Activity Rs m-1,959-386 507.9%  
Net Cashflow Rs m4,240-6,125 -69.2%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 2.0 145.0%  
FIIs % 9.1 1.6 568.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 21.5 64.7%  
Shareholders   49,328 41,647 118.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   CIPLA  PFIZER  DR. DATSONS LABS  SHASUN PHARMA  SANOFI INDIA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS